Imprivata Helps Healthcare Providers in New York State Meet I-STOP Requirements for Electronic Prescribing of Controlled Substances

Imprivata Webinar on February 10 to Bring Together Leading Industry Experts to Help Hospitals and Providers Better Understand Regulatory and Technology Requirements for EPCS

Lexington, Mass.—January 20, 2015—Healthcare providers in New York State have until March 27, 2015 to implement electronic prescribing of controlled substances (EPCS) to comply with the state’s I-STOP Act. Imprivata® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, is working with hospitals and providers across New York State to help them meet DEA and I-STOP requirements while also ensuring EPCS is easy and convenient for providers. Imprivata has also worked closely with leading industry experts to create whitepapers, FAQs, and in-depth insights into best practices for understanding regulatory and technology requirements for EPCS, available at

“New York’s landmark I-STOP legislation has the potential to significantly reduce prescription drug abuse and addiction, but there are a number of complexities to the law that prescribers must address before they can implement EPCS,” said Clay Ritchey, chief marketing officer at Imprivata. “Imprivata is working closely with prescribers across the state to understand both the DEA and I-STOP requirements for EPCS. We are also leveraging our experience and deep understanding of clinical workflows to help prescribers implement solutions that enable fast, secure e-Prescribing of all medications—including controlled substances—through a single process integrated directly into the EMR.”

To help hospitals and providers in New York understand the technical and regulatory requirements for EPCS, Imprivata will host a webinar titled “I-STOP: Your Questions Answered Live” on Tuesday, February 10, 2015 at 2 p.m. ET. Participants will be able to ask leading experts about the I-STOP and DEA legislation, technology options, and best practices to manage process challenges for EPCS.

“Navigating through the DEA and state-level regulatory requirements for EPCS can be daunting, and healthcare administrators and providers are looking for guidance. Imprivata has taken a leadership role in helping organizations understand the legislation and think about best ways to approach a solution,” said William T. Winsley, MS, RPh, past president of the National Association of Boards of Pharmacy and former executive director of the Ohio State Board of Pharmacy. “Imprivata has brought together leading industry experts and created valuable resources that will help healthcare providers in New York and across the country successfully implement EPCS as an important step toward addressing America’s prescription drug abuse epidemic.”

About Imprivata
Imprivata (NYSE: IMPR) is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit


Media Contact:                                   
Dan Borgasano

Investor Contact:
Bob East / Asher Dewhurst
Westwicke Partners